DiaMedica Therapeutics Stock Forecast, Price & News

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

Is DiaMedica Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics or view top-rated stocks.

How has DiaMedica Therapeutics' stock been impacted by Coronavirus (COVID-19)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DMAC stock has decreased by 15.5% and is now trading at $3.38.
View which stocks have been most impacted by COVID-19.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 61,500 shares, a decline of 22.4% from the December 15th total of 79,300 shares. Based on an average trading volume of 161,700 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the stock are sold short.
View DiaMedica Therapeutics' Short Interest.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for DiaMedica Therapeutics.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. During the same period last year, the company earned ($0.19) EPS.
View DiaMedica Therapeutics' earnings history.

What price target have analysts set for DMAC?

3 brokerages have issued 12 month target prices for DiaMedica Therapeutics' stock. Their forecasts range from $11.00 to $27.00. On average, they anticipate DiaMedica Therapeutics' share price to reach $20.50 in the next year. This suggests a possible upside of 506.5% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics or view top-rated stocks among Wall Street analysts.

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:

• Rick John Pauls, President. Chief Executive Officer & Director
• Scott Kellen, Chief Financial Officer & Secretary
• Harry W. Alcorn, Chief Medical Officer & VP-Clinical Affairs (LinkedIn Profile)
• Sydney A. Gilman, Vice President-Regulatory Affairs

Who are some of DiaMedica Therapeutics' key competitors?

Some companies that are related to DiaMedica Therapeutics include XOMA (XOMA), Pieris Pharmaceuticals (PIRS), Leap Therapeutics (LPTX), Werewolf Therapeutics (HOWL), Milestone Pharmaceuticals (MIST), 89bio (ETNB), Eliem Therapeutics (ELYM), Summit Therapeutics (SMMT), Aerovate Therapeutics (AVTE), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), Harrow Health (HROW), Epizyme (EPZM), Capstar Special Purpose Acquisition (CPSR) and Gelesis (GLS).
View all of DMAC's competitors.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $3.38.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics has a market capitalization of $63.50 million. The company earns $-12.29 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does DiaMedica Therapeutics have?

DiaMedica Therapeutics employs 11 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

Where are DiaMedica Therapeutics' headquarters?

DiaMedica Therapeutics is headquartered at 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at (763) 312-6755 or via email at [email protected].